63rd ASH Annual Meeting and Exposition
December 11-14, 2021

AML

  • COVID and beyond
  • Outcomes and Omics Potpourri
  • Practice-changing studies

613. Acute Myeloid Leukemia: Clinical and Epidemiological: COVID and beyond

217

Akriti G Jain, Ning C. Dong, Somedeb Ball, et al.

The vast majority of patients with AML and MDS were seropositive after two doses of the vaccine. Most clinical and laboratory variables did not affect the seropositivity rate. The antibody titer values rose sharply after the 2nd vaccination dose. This indicates the benefit of serial vaccination (i.e. additional dosing) in poorly responding patients. The mRNA-273 SARS-CoV-2 vaccine induces a strong humoral response in this study group of AML- and MDS-patients.

 

218

Jil Rotterdam, Margot Thiaucourt, Juliana Schwaab, et al.

In patients with low-grade NHL, MDS and autoimmune diseases, no or only a weak immune response was measured after the 2nd COVID vaccination. Patients with MPN seem to respond slightly better, and CML patients have no problems.

 

219 ASH denotes this abstract as clinically relevant

Isla M. Johnson, Evandro D. Bezerra, Faiqa Farrukh, et al.

In AML patients taking Venetoclax + HMA, cardiac complications occurred in 20 percent, although around 30 percent of these patients had no pre-existing heart disease; the mortality was 27 percent.

 

220

Xu Wang, Ian Thomas, Cono Ariti, et al.

The consideration of cytogenetic risk, FLT3-ITD and NPM1 mutation status only improved the prognostic accuracy minimally. This also applies to some of the QLQ-C30 subscales. The study results indicate the difficulty of predicting outcomes of non-intensive AML therapy with routinely available clinical baseline data.

 

221

Karilyn Larkin, Deedra Nicolet, Ben Kelly, et al.

Black AYA-AML patients have distinct molecular features (including high frequencies of CBF-AML and low frequencies of NPM1). The age group between 18 and 29 years of age is primarily responsible for the race-related disparity in survival, especially those without CBF with very poor survival. The lower CR rates combined with persistent dominant clones at relapse indicate a reduced response to induction chemotherapy. This indicates different treatment intensities and / or modalities required in these patients. High rates of premature death indicate delays in diagnosis and care. This means that systematic health inequalities, especially in this population group, must be changed.

 

222

Gi June Min, Byung Sik Cho, Sung-Soo Park, et al.

The prognostic value of the physical and psychological assessment by GA for the survival results in intensively treated eAML patients could be proven with this study. Non-fatal toxicities during intensive chemotherapy in eAML patients could be identified based on cognitive and physical impairments. These study results will facilitate the integration of GA measures into validated survival prediction models. This will lead the way in determining the initial treatment of eAML patients in routine clinical care and clinical trials.

613. Acute Myeloid Leukemia: Clinical and Epidemiological: Outcomes and Omics Potpourri

613. Acute Myeloid Leukemia: Clinical and Epidemiological: Practice-changing studies

793

Sergej Konoplev, Guilin Tang, Xiaoqiong Wang, et al.

According to the study results, it is recommended that all myeloid neoplasms with KMT2A (MLL) rearrangement be classified as AML, regardless of the number of blasts.

 

794

Sangeetha Venugopal, Tapan M. Kadia, Farhad Ravandi, et al.

In patients with ts-AML and previous exposure to HMA, HMA + Ven resulted in significantly higher ORR rates and improved OS compared to IC / LIC, especially in patients with a  non-adverse risk karyotype and in patients 60 years of age or more. Thus, instead of chemotherapy-based therapies, HMA + Ven should be preferred in patients with ts-AML and previous exposure to HMA. The study results also confirm the very poor outcome results of ts-AML. This is a poor risk subgroup of AML where new, effective therapies are needed.

 

795

Andrew Matthews, Alexander E. Perl, Selina M. Luger, et al.

The study found no statistically significant difference in overall survival between induction with CPX-351 and ven/aza.

796

Ga-Young Song, Taehyung Kim, Seo-Yeon Ahn, et al.

The presence of STM is an independent unfavorable prognostic factor for AML. This can be overcome through allogeneic HCT.

 

797

Talha Badar, Mark R. Litzow, Rory M. Shallis, et al.

Despite generally poor results, in a subgroup of these patients, alloHCT appears to improve long-term survival.

 

798

Musa Yilmaz, Hagop Kantarjian, Nicholas J. Short, et al.

First and second-generation FLT3i-based doublet therapies generated comparable response rates. The survival rate in older adults with newly diagnosed FLT3 mutated AML was 9-16 months. The triplet combination was able to significantly improve the CR / CRi rates, the FLT3-PCR and MFC-MRD rates, and also the overall survival. The early mortality in this retrospective analysis was not increased. Prospective validation of triplet therapy in older and/or unfit AML patients would be desirable.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close